What is TRAW's earnings growth forecast for 2025-2025?
(NASDAQ: TRAW) Traws Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.28%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.17%.
Traws Pharma's earnings in 2025 is -$54,674,000.
In 2025, TRAW is forecast to generate -$171,240,413 in earnings, with the lowest earnings forecast at -$171,240,413 and the highest earnings forecast at -$171,240,413.
What is TRAW's revenue growth forecast for 2025-2025?
(NASDAQ: TRAW) Traws Pharma's forecast annual revenue growth rate of 11.31% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.48%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.37%.
Traws Pharma's revenue in 2025 is $226,000.
In 2025, TRAW is forecast to generate $1,166,972 in revenue, with the lowest revenue forecast at $1,166,972 and the highest revenue forecast at $1,166,972.
What is TRAW's forecast return on assets (ROA) for 2025-2028?
(NASDAQ: TRAW) forecast ROA is -589.46%, which is lower than the forecast US Biotechnology industry average of 36.07%.
What is TRAW's Earnings Per Share (EPS) forecast for 2025-2025?
(NASDAQ: TRAW) Traws Pharma's current Earnings Per Share (EPS) is -$35.21. In 2025, TRAW's EPS is forecast to hit -$33.75 (min: -$33.75, max: -$33.75).
What is TRAW's forecast return on equity (ROE) for 2025-2028?
(NASDAQ: TRAW) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.